162 related articles for article (PubMed ID: 24748192)
1. [Expression of serum GDF15 and its clinical significance in multiple myeloma patients].
Zhao N; Yang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Mar; 39(3):270-5. PubMed ID: 24748192
[TBL] [Abstract][Full Text] [Related]
2. [Expression of Blimp-1 mRNA in Bone Marrow Mononuclear Cells in Multiple Myeloma Patients and Its Clinical Significance].
Hu WT; Liu JW; Liu HC; Wang TT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1443-1448. PubMed ID: 27784372
[TBL] [Abstract][Full Text] [Related]
3. Association of Growth Differentiation Factor-15 Polymorphisms and Growth Differentiation Factor-15 Serum Levels with Susceptibility to Multiple Myeloma in a Chinese Population.
Li R; Hu Z; Chen H; Lu Y; Qin S; Huang C; Yao Y; Qin X; Wang C
Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491432
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of serum levels of Dickkopf-1 (DKK-1) in monoclonal gammopathy of undetermined significance and multiple myeloma].
Ščudla V; Petrová P; Pika T; Lochman P; Minařík J; Bačovský J; Srovnalík K
Cas Lek Cesk; 2015; 154(4):181-8. PubMed ID: 26357861
[TBL] [Abstract][Full Text] [Related]
5. Elevated level of serum growth differentiation factor 15 is associated with oral leukoplakia and oral squamous cell carcinoma.
Yang CZ; Ma J; Luo QQ; Neskey DM; Zhu DW; Liu Y; Myers JN; Zhang CP; Zhang ZY; Zhong LP
J Oral Pathol Med; 2014 Jan; 43(1):28-34. PubMed ID: 23710769
[TBL] [Abstract][Full Text] [Related]
6. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
8. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients.
Tarkun P; Birtas Atesoglu E; Mehtap O; Musul MM; Hacihanefioglu A
Acta Haematol; 2014; 131(3):173-8. PubMed ID: 24216602
[TBL] [Abstract][Full Text] [Related]
9. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
10. Increased Plasma GDF15 Is Associated with Altered Levels of Soluble VEGF Receptors 1 and 2 in Symptomatic Multiple Myeloma.
Hidman J; Larsson A; Thulin M; Karlsson T
Acta Haematol; 2022; 145(3):326-333. PubMed ID: 34818652
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma.
Corre J; Labat E; Espagnolle N; Hébraud B; Avet-Loiseau H; Roussel M; Huynh A; Gadelorge M; Cordelier P; Klein B; Moreau P; Facon T; Fournié JJ; Attal M; Bourin P
Cancer Res; 2012 Mar; 72(6):1395-406. PubMed ID: 22301101
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
13. Association between Growth Differentiation Factor 15 (GDF15) and Cardiovascular Risk in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
Shin MY; Kim JM; Kang YE; Kim MK; Joung KH; Lee JH; Kim KS; Kim HJ; Ku BJ; Shong M
J Korean Med Sci; 2016 Sep; 31(9):1413-8. PubMed ID: 27510384
[TBL] [Abstract][Full Text] [Related]
14. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
15. Increased serum levels of MIC1/GDF15 correlated with bone erosion in spondyloarthritis: A pilot study.
Song Y; Cui Y; Zhang X; Lin H; Zhang G; Zeng H; Zeng Y
Medicine (Baltimore); 2018 Dec; 97(51):e13733. PubMed ID: 30572513
[TBL] [Abstract][Full Text] [Related]
16. The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes.
He X; Su J; Ma X; Lu W; Zhu W; Wang Y; Bao Y; Zhou J
Cardiovasc Diabetol; 2020 Mar; 19(1):40. PubMed ID: 32222153
[TBL] [Abstract][Full Text] [Related]
17. Serum Growth Differentiation Factor 15 in Parkinson Disease.
Yao X; Wang D; Zhang L; Wang L; Zhao Z; Chen S; Wang X; Yue T; Liu Y
Neurodegener Dis; 2017; 17(6):251-260. PubMed ID: 28787735
[TBL] [Abstract][Full Text] [Related]
18. Growth differentiation factor 15 (GDF15) promotes osteoclast differentiation and inhibits osteoblast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease.
Westhrin M; Moen SH; Holien T; Mylin AK; Heickendorff L; Olsen OE; Sundan A; Turesson I; Gimsing P; Waage A; Standal T
Haematologica; 2015 Dec; 100(12):e511-4. PubMed ID: 26294726
[No Abstract] [Full Text] [Related]
19. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
20. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
